Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Nuclear factor-kappaB in development, prevention, and therapy of cancer.

Van Waes C.

Clin Cancer Res. 2007 Feb 15;13(4):1076-82. Review.

2.

Nuclear factor-kappaB activation: from bench to bedside.

Sethi G, Sung B, Aggarwal BB.

Exp Biol Med (Maywood). 2008 Jan;233(1):21-31. Review.

PMID:
18156302
3.

NF-kappaB as a potential molecular target for cancer therapy.

Lee CH, Jeon YT, Kim SH, Song YS.

Biofactors. 2007;29(1):19-35. Review.

PMID:
17611291
4.

NF-kappaB: a potential target for cancer chemoprevention and therapy.

Sarkar FH, Li Y.

Front Biosci. 2008 Jan 1;13:2950-9. Review.

PMID:
17981768
5.

The NF-kappaB transcription factor pathway as a therapeutic target in cancer: methods for detection of NF-kappaB activity.

Mauro C, Zazzeroni F, Papa S, Bubici C, Franzoso G.

Methods Mol Biol. 2009;512:169-207. doi: 10.1007/978-1-60327-530-9_10.

PMID:
19347278
6.

The transcription factor nuclear factor-kappa B and cancer.

Escárcega RO, Fuentes-Alexandro S, García-Carrasco M, Gatica A, Zamora A.

Clin Oncol (R Coll Radiol). 2007 Mar;19(2):154-61. Review.

PMID:
17355113
7.

NF-kappaB as a therapeutic target in cancer.

Orlowski RZ, Baldwin AS Jr.

Trends Mol Med. 2002 Aug;8(8):385-9. Review.

PMID:
12127724
9.

Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis.

Pandey MK, Sung B, Kunnumakkara AB, Sethi G, Chaturvedi MM, Aggarwal BB.

Cancer Res. 2008 Jul 1;68(13):5370-9. doi: 10.1158/0008-5472.CAN-08-0511.

10.

Identification of a novel blocker of IkappaBalpha kinase activation that enhances apoptosis and inhibits proliferation and invasion by suppressing nuclear factor-kappaB.

Sung B, Pandey MK, Nakajima Y, Nishida H, Konishi T, Chaturvedi MM, Aggarwal BB.

Mol Cancer Ther. 2008 Jan;7(1):191-201. doi: 10.1158/1535-7163.MCT-07-0406.

11.
12.

Aberrant constitutive activation of nuclear factor kappaB in glioblastoma multiforme drives invasive phenotype.

Raychaudhuri B, Han Y, Lu T, Vogelbaum MA.

J Neurooncol. 2007 Oct;85(1):39-47.

PMID:
17479228
13.

Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth.

Sakamoto K, Maeda S, Hikiba Y, Nakagawa H, Hayakawa Y, Shibata W, Yanai A, Ogura K, Omata M.

Clin Cancer Res. 2009 Apr 1;15(7):2248-58. doi: 10.1158/1078-0432.CCR-08-1383.

14.

Targeting NF-kappaB in hematologic malignancies.

Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, Kroemer G.

Cell Death Differ. 2006 May;13(5):748-58. Review.

15.
16.

Inflammatory NF-kappaB activation promotes hepatic apolipoprotein B100 secretion: evidence for a link between hepatic inflammation and lipoprotein production.

Tsai J, Zhang R, Qiu W, Su Q, Naples M, Adeli K.

Am J Physiol Gastrointest Liver Physiol. 2009 Jun;296(6):G1287-98. doi: 10.1152/ajpgi.90540.2008.

17.

Marasmius oreades substances block NF-kappaB activity through interference with IKK activation pathway.

Petrova RD, Mahajna J, Wasser SP, Ruimi N, Denchev CM, Sussan S, Nevo E, Reznick AZ.

Mol Biol Rep. 2009 Apr;36(4):737-44. doi: 10.1007/s11033-008-9237-0.

PMID:
18386159
18.

NF-kappaB signaling pathway and its therapeutic implications in human diseases.

Sarkar FH, Li Y, Wang Z, Kong D.

Int Rev Immunol. 2008;27(5):293-319. doi: 10.1080/08830180802276179. Review.

PMID:
18853341
19.

Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells.

Rahman KM, Ali S, Aboukameel A, Sarkar SH, Wang Z, Philip PA, Sakr WA, Raz A.

Mol Cancer Ther. 2007 Oct;6(10):2757-65.

20.
Items per page

Supplemental Content

Support Center